However, with 12 h of bortezomib treatment, we did not observe a reduction in Fanconi anaemia (FA) complementation group D2 (FANCD2) or RAD51 (electronic supplementary material, figure S4A), two factors that were depleted in multiple myeloid cells upon similar treatment [64]. This evidence concerns the gene FANCD2 and Friedreich ataxia.